Status:
UNKNOWN
HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors
Lead Sponsor:
Asan Medical Center
Conditions:
Acute Leukemia
Myelodysplastic Syndrome
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE1
PHASE2
Brief Summary
RATIONALE: Conditioning with total body irradiation (TBI) and fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of HLA-h...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Disease characteristics
- Acute lymphoblastic leukemia (first remission, high risk; beyond first remission; refractory)
- Acute myeloblastic leukemia (first remission, high risk; beyond first remission; refractory)
- Myelodysplastic syndrome
- Solid tumors (Refractory/relapse)
- No HLA-identical family member or closely matched (8 or 7 of 8 HLA-locus match) unrelated marrow donor available
- HLA-haploidentical related donor available
- Exclusion criteria
- Active fungal infections
- HIV positive
- Pregnant or nursing
Exclusion
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01509300
Start Date
January 1 2012
End Date
March 1 2014
Last Update
January 13 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736